The pharmaceutical industry is currently facing an unprecedented analytical mandate. Driven by tightening global regulations from the European Chemicals Agency (ECHA), the US Environmental Protection Agency (EPA), and evolving pharmacopeial standards in 2025 and 2026, per- and polyfluoroalkyl substances (PFAS) are being heavily restricted.
While much of the public focus has been on environmental water testing, pharmaceutical manufacturers are now under the microscope. The industry relies heavily on fluoropolymers for their chemical resistance and low-friction properties. PFAS are ubiquitous in pharmaceutical manufacturing and packaging, found in sterile filters, pump seals, fluoropolymer-coated elastomer stoppers, blister packaging, and even as trace contaminants in complex excipients.
To ensure patient safety and regulatory compliance, extractables and leachables (E&L) testing must now routinely screen for "forever chemicals." Because these compounds bioaccumulate, regulatory thresholds are incredibly low, demanding part-per-trillion (ppt) or sub-nanogram-per-liter sensitivity. To achieve this, separation scientists are relying on high-performance Liquid Chromatography coupled with tandem mass spectrometry (LC-MS/MS). However, running trace PFAS analysis on standard LC equipment is a recipe for false positives and analytical failure.
Working in analytical science?
Register for a FREE Separation Science account to subscribe to the Separation Science Newsletter.
The LC-MS/MS Imperative and the Matrix Challenge
To reach the ultra-trace detection limits required by emerging mandates, triple quadrupole (QqQ) mass spectrometers operating in multiple reaction monitoring (MRM) mode are the absolute gold standard. MRM provides the extreme selectivity needed to isolate specific PFAS precursor-to-product ion transitions amidst heavy background noise.
However, pharmaceutical sample matrices—such as highly concentrated excipients, liposomal formulations, or aggressively extracted polymer packaging—present severe ion suppression challenges in the electrospray ionization (ESI) source. Separation scientists must carefully design their chromatographic gradients, typically using reversed-phase C18 columns with methanol/water or acetonitrile/water mobile phases heavily modified with ammonium acetate, to ensure adequate retention and separation of both short-chain (for example, PFBA) and long-chain (such as PFOS and PFOA) perfluoroalkyl acids from suppressing matrix components.
The Ghost in the Machine: System Background Contamination
The most formidable hurdle in pharmaceutical PFAS analysis isn't the sample matrix; it is the analytical instrument itself.
Standard HPLC and UHPLC systems are engineered with fluoropolymer components throughout the flow path to resist highly corrosive solvents. Polytetrafluoroethylene (PTFE) and fluorinated ethylene propylene (FEP) are routinely used in solvent delivery lines, pump seals, vacuum degasser membranes, and autosampler rotor seals.
When you are attempting to quantify PFAS at 10 ppt in a leachable study, a standard LC system might continuously leach 50 ppt of system-related PFAS into the mobile phase. This continuous leaching creates artificially elevated baselines, severe ghost peaks, and renders accurate trace quantitation completely impossible. Without significant hardware modifications, standard LC systems are fundamentally incompatible with modern PFAS testing limits.
The Mandatory Hardware Retrofit: The Delay Column
To achieve regulatory compliance, the LC system must be systematically de-fluorinated and modified to isolate the remaining background contamination. The single most important hardware modification is the installation of an isolator column (also known as a delay column).
A delay column is a small C18 or highly retentive reversed-phase trap column installed in a highly specific location: between the pump mixer and the autosampler injection valve.
Here is how it works: Any PFAS leaching from the solvent bottles, degasser, or pump components will be temporarily trapped by this delay column. When the gradient begins, these system-related PFAS are retained and delayed chromatographically. Meanwhile, the injected sample—which contains the actual target PFAS—bypasses the delay column completely, entering the flow path at the autosampler valve and traveling directly to the primary analytical column.
The result? The mass spectrometer detects two distinct chromatographic peaks for the exact same MRM transition. The first peak is the true PFAS concentration from the pharmaceutical sample. The second, later-eluting peak is the background system contamination, safely resolved away from the analyte of interest.
De-Fluorinating the LC System and Flow Path
While the delay column traps pump-related contamination, any PTFE located after the autosampler will still directly contaminate the sample peak. Therefore, rigorous hardware swapping is required:
Tubing Swaps: Replace all fluoropolymer (PTFE/FEP) tubing from the solvent reservoirs to the autosampler with high-purity PEEK (Polyetheretherketone) or passivated stainless steel tubing.
Solvent Filters: Standard glass solvent bottle sinkers often contain PTFE frits. These must be replaced with stainless steel or specialized PFAS-free UHMWPE (Ultra-High-Molecular-Weight Polyethylene) frits.
The Degasser Bypass: Polymeric vacuum degasser membranes are a notorious source of persistent background PFAS. For ultra-trace analysis, laboratories often bypass the internal LC degasser entirely, relying instead on offline ultrasonic degassing or continuous helium sparging of the mobile phases.
Sample Preparation and Reagent Best Practices
Trace PFAS analysis requires a paradigm shift in standard laboratory handling procedures. Minor oversights in sample preparation can easily invalidate an entire E&L study.
Ditch the Glass: Unlike most organic molecules, long-chain PFAS (including PFOS and PFDA) are highly prone to sorptive losses on borosilicate glass surfaces. Do not use standard glass autosampler vials, glass pipettes, or glass sample preparation vessels. Transition entirely to high-quality polypropylene (PP) vials and tubes.
Certify Your Polypropylene: Not all plastic is created equal. Many bulk polypropylene centrifuge tubes are manufactured using mold-release agents that contain fluorinated compounds. Ensure all consumables are explicitly batch-tested and certified PFAS-free.
Reagent Purity: Do not trust standard LC-MS grade solvents. Even high-purity water and methanol can contain ppt levels of PFAS from the manufacturing facility's plumbing. Procure specific PFAS-analyzed reagents and run rigorous, multi-injection blank sequences to verify the cleanliness of the mobile phase before analyzing highly regulated pharmaceutical batches.
